China rolls out ethical guideline for brain-computer interfaces research

BEIJING / WAM

China has rolled out an ethical guideline for brain-computer interfaces (BCI) aiming to better guide the compliant development of BCI research and prevent ethical risks in the process of research and technological applications.
The released guideline by the Ministry of Science and Technology comes after Tesla CEO Elon Musk announced the success of a procedure to implant Neuralink’s brain chip into the first human patient.
This guideline, compiled by the artificial intelligence ethics subcommittee of the National Committee for Science and Technology Ethics, released by the Ministry, serves as a reference for scientific research institutions and researchers.
It outlines the basic principles to be followed in conducting BCI research which are safeguarding health and enhancing well-being, respecting subjects involved and apply the technology on them moderately, adhering to fairness and ensuring equity, risk management and ensuring safety, information disclosure and ensuring informed consent, supporting innovation and strict regulation.
For rare diseases that seriously endanger life and have no other effective treatment methods, clinical trials of innovative BCI products can be conducted with full informed consent under strict compliance with national regulations on medical devices and clinical research, the guideline pointed out.
The guideline highlights that research that replaces or weakens human judgment and decision-making abilities, significantly interferes with or blurs human autonomy and self-awareness should be avoided, when enhanced BCI
technologies have yet been fully proven to be superior to human capabilities and have gained social consensus.
The guideline puts forward specific requirements in seven aspects, including legality and compliance, social and scientific values, informed consent, privacy protection and personal information protection, risk prevention and control, qualification requirements, and responsibility mechanisms.
It says that BCI research should establish a safety risk prevention and control mechanism, including strict operating procedures, common error correction mechanisms, emergency plans, suspension procedures and emergency remedial guidelines to ensure the safety of subjects. BCI research should also enhance system transparency, interpretability, reliability and controllability, ensuring accountability in technology design, development, use, deployment and other stages.
Zhang Linghan, professor of law at the China University of Political Science and Law in Beijing, welcomed the guideline. She told the Global Times that it is a timely basic reference for BCI researchers.
In specific human experimentation studies, there may be ethical conflicts between the health benefits of the subjects and the scientific development and social benefits, she noted, adding that the scientific development, achievements of researchers and health benefits to the public are also based on the risks, contributions, and even certain harm to and sacrifice of these subjects.
The guideline also provides ethical guidelines for five types of research: non-invasive restorative BCI research, invasive restorative BCI research, interventional BCI research, enhanced BCI research, and animal BCI research.
Specifically, non-invasive restorative BCI research collects patients’ brain signals in a non-invasive manner and decodes the signals to control external devices, improving patients’ motor and communication functions. Invasive restorative brain-machine interfaces involve neurosurgical procedures and implant placement, which pose short-term and long-term safety risks. Research in this area should comply with relevant national laws, regulations, and standards, adhere to medical ethics norms, and monitor long-term safety risks, including brain injury.
Interventional brain-machine interfaces involve interventional surgery and placement of intravascular implants, and monitoring long-term infection risks associated with implanted devices and closely observing adverse reactions such as intravascular thrombosis, the guideline reads.
The guideline clarifies that enhanced BCI refers to brain-machine interface technologies that enhance users’ perception, cognition, and motor abilities of normal bodily functions. They are generally non-invasive and require a thorough examination of risks and benefits and minimisation of negative impacts on humans.
Research that may cause addiction, affect normal human thinking and behavior should be strictly controlled, it stresses.
Zhang noted that the guideline highlights China’s long-standing value placed on the protection of subjects in medical research.
Health authorities established a Biomedical Research Ethics Review Committee involving human subjects and formulated the Guidelines for Ethical Review of Medical Research in 1998 and then the Ministry of Health promulgated and implemented the measures for ethical review of biomedical research involving humans on January 11, 2007, in accordance with the relevant provisions of the Physician Law and the Regulations on the Administration of Medical Institutions.
These regulations clearly state that all research involving human subjects must comply with the World Medical Association’s Declaration of Helsinki, which emphasises fairness, respect for human dignity, maximising the benefits to subjects, and minimising harm as much as possible, Zhang noted.